Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Sridhar, SS
  • Hotte, SJ
  • Mackenzie, MJ
  • Kollmannsberger, C
  • Haider, MA
  • Pond, Gregory
  • Chen, EX
  • Srinivasan, R
  • Ivy, SP
  • Moore, MJ

publication date

  • June 20, 2007